# A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

> **NCT07748208** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer
- Diabetes Type II

## Interventions

- **DRUG:** Inavolisib
- **DRUG:** Fulvestrant
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT07748208
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2029-06-15
- **Final completion:** 2029-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748208, "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*